Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21702035 | 1.00 | CTSL (0.48) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL26494777 | 0.96 | CTSL (0.47) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL23712029 | 0.96 | CTSL (0.49) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL21702176 | 0.96 | CTSL (0.49) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL26494560 | 0.94 | CTSL (0.48) | CTSLCTSSCTSKRENF2RL1 | |
| SCHEMBL26494573 | 0.94 | CTSL (0.46) | CTSLCTSSCTSKRENF2RL1 | |
| SCHEMBL26494547 | 0.93 | CTSS (0.45) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL26494793 | 0.93 | CTSL (0.45) | CTSLCTSSCTSKRENCTSB | |
| SCHEMBL26494652 | 0.93 | CTSL (0.48) | CTSLCTSSCTSKRENF2RL1 | |
| SCHEMBL26494685 | 0.93 | CTSS (0.49) | CTSLCTSSCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | CTSL 1/4885CTSS 3/4885CTSK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.